- ICH GCP
- US Clinical Trials Registry
- Search trials
Clinical Trials Sponsored by SL BIGEN
Total 825 results
-
Reata, a wholly owned subsidiary of BiogenCompletedFocal Segmental Glomerulosclerosis | IgA Nephropathy | Autosomal Dominant Polycystic Kidney | CKD Associated With Type 1 DiabetesUnited States
-
Reata, a wholly owned subsidiary of BiogenCompletedChronic Kidney DiseasesUnited States
-
Reata, a wholly owned subsidiary of BiogenCompletedIdiopathic Pulmonary Fibrosis | Pulmonary Arterial Hypertension | Pulmonary Hypertension | Interstitial Lung Disease | Sarcoidosis | Idiopathic Interstitial Pneumonia | Cryptogenic Organizing Pneumonia | Desquamative Interstitial Pneumonia | Respiratory Bronchiolitis Associated Interstitial Lung Disease and other conditionsUnited States, Germany
-
Reata, a wholly owned subsidiary of BiogenTerminatedBrain MetastasesUnited States
-
Reata, a wholly owned subsidiary of BiogenCompleted
-
Reata, a wholly owned subsidiary of BiogenTerminatedDiabetes Mellitus, Type 2 | Renal Insufficiency, Chronic
-
Reata, a wholly owned subsidiary of BiogenCompletedAlport SyndromeUnited States, United Kingdom, Japan, Australia, France, Germany, Puerto Rico, Spain
-
Reata, a wholly owned subsidiary of BiogenTerminatedLeptomeningeal CarcinomatosisUnited States
-
Reata, a wholly owned subsidiary of BiogenCompletedDiabetic Nephropathy | Type 2 Diabetes | Chronic Kidney DiseaseUnited States
-
Reata, a wholly owned subsidiary of BiogenCompleted
-
Reata, a wholly owned subsidiary of BiogenCompleted
-
Reata, a wholly owned subsidiary of BiogenCompletedAdvanced Solid Tumors | Lymphoid MalignanciesUnited States
-
Reata, a wholly owned subsidiary of BiogenTerminatedPancreatic Neoplasms | Pancreatic CancerUnited States
-
Reata, a wholly owned subsidiary of BiogenNo longer available
-
Duke UniversityEigenRecruitingUterine CancerUnited States
-
Sage TherapeuticsBiogenRecruitingMajor Depressive DisorderUnited States
-
Stanford UniversityBiogenActive, not recruitingMyotonic Dystrophy 1United States
-
BiogenApple Inc.TerminatedMild Cognitive Impairment | Normal AgingUnited States
-
Eisai Inc.BiogenActive, not recruitingAlzheimer's DiseaseUnited States, Canada, France, Germany, Italy, Japan, Korea, Republic of, Netherlands, Spain, Sweden, United Kingdom
-
BiogenAlkermes, Inc.CompletedMultiple SclerosisUnited States, Bulgaria, Poland, Belgium, Canada, Germany, Russian Federation, Serbia, Spain, Ukraine
-
Rigshospitalet, DenmarkBiogenCompletedPrimary Progressive Multiple SclerosisDenmark
-
BiogenElan PharmaceuticalsCompletedRelapsing Remitting Multiple Sclerosis (RRMS)Belgium, Mexico, Poland, Romania, Saudi Arabia, Ukraine
-
BiogenElan PharmaceuticalsCompleted
-
UCB PharmaBiogenCompletedImmune System Diseases | Autoimmune Diseases | Lupus Erythematosus, Systemic | Skin and Connective Tissue Diseases | Connective Tissue DiseaseBulgaria, Belgium, Germany, Poland, Romania, Russian Federation, Spain
-
BiogenElan PharmaceuticalsCompletedRelapsing Remitting Multiple SclerosisUnited States, Germany, Spain
-
BiogenElan PharmaceuticalsCompletedMultiple SclerosisUnited States
-
BiogenElan PharmaceuticalsCompletedSafety and Efficacy of Natalizumab in Combination With Avonex in the Treatment of Multiple SclerosisMultiple Sclerosis, Relapsing-RemittingUnited States, Germany, Austria, Belgium, France, Israel, Italy
-
BiogenElan PharmaceuticalsCompletedMultiple Sclerosis, Relapsing-Remitting
-
Reata, a wholly owned subsidiary of BiogenRecruitingA Phase 2 Study of RTA 901 in Patients With Diabetic Peripheral Neuropathic Pain (CYPRESS) (CYPRESS)Diabetic Peripheral Neuropathic PainUnited States
-
Reata, a wholly owned subsidiary of BiogenCompletedHealthy VolunteersUnited States
-
Reata, a wholly owned subsidiary of BiogenCompleted
-
Reata, a wholly owned subsidiary of BiogenCompletedHepatic ImpairmentUnited States
-
Reata, a wholly owned subsidiary of BiogenCompleted
-
Reata, a wholly owned subsidiary of BiogenCompleted
-
Reata, a wholly owned subsidiary of BiogenWithdrawnDiabetes Mellitus, Type 2 | Renal Insufficiency, Chronic
-
Reata, a wholly owned subsidiary of BiogenTerminatedLiver DiseaseUnited States
-
Reata, a wholly owned subsidiary of BiogenTerminatedDiabetes Mellitus, Type 2 | Renal Insufficiency, Chronic
-
Reata, a wholly owned subsidiary of BiogenWithdrawn
-
Reata, a wholly owned subsidiary of BiogenCompleted
-
Reata, a wholly owned subsidiary of BiogenWithdrawnDiabetes Mellitus, Type 2 | Renal Insufficiency, Chronic
-
Reata, a wholly owned subsidiary of BiogenCompletedHealthy | Hepatic ImpairmentUnited States
-
Reata, a wholly owned subsidiary of BiogenAbbVieCompletedOcular Inflammation | Ocular Pain | Corneal Endothelial Cell Loss | Cataract SurgeryUnited States
-
Reata, a wholly owned subsidiary of BiogenAbbVieCompletedInflammation and Pain Following Ocular SurgeryUnited States
-
Reata, a wholly owned subsidiary of BiogenAbbVieCompletedMItochondrial MyopathiesUnited States, Denmark
-
Reata, a wholly owned subsidiary of BiogenAbbVieCompleted
-
Sage TherapeuticsBiogenCompleted
-
Sage TherapeuticsBiogenCompletedMajor Depressive DisorderUnited States
-
BiogenElan PharmaceuticalsCompletedMultiple SclerosisUnited States, Puerto Rico
-
Eisai Inc.BiogenActive, not recruitingEarly Alzheimer's DiseaseUnited States, Spain, Korea, Republic of, China, United Kingdom, Australia, Canada, France, Germany, Italy, Japan, Russian Federation, Singapore, Sweden